Codexis Inc recorded a cumulative net loss of $-31 million during 12 month ending in the second quarter 2026.
The Basic Materials sector has seen employees of 53 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3226, from total ranking in previous quarter at 3987.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CDXS Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-210,432	-219,110	-301,192	-438,021	-445,041
CDXS's Total Ranking	# 3226	# 3987	# 3623	# 3663	# 3744
Seq. Net Income Change	-	-	-	-	-

CDXS Company Profile >> Back to CDXS Efficiency Comparisons >> Compare CDXS Net Income per Employee to its Competitors

CDXS Net Income per Employee Company Ranking
Within:	No.
Chemical Manufacturing Industry	# 54
Basic Materials Sector	# 210
Overall Market	# 3226

Net Income per Employee Statistics
High	Average	Low
$ -9,548	$ -206,087	$ -559,260
(Jun 30 2016)		(Sep 30 2023)

News about Codexis inc Income per employee

Codexis Strategically Bolsters Talent Pool Amid Financial Struggles

In the challenging landscape of the biotechnology industry, Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions, has recently taken significant steps to enhance its financial resilience while simultaneously expanding its workforce. On October 14, 2024, the company announced several employment inducement grants aimed not only at attracting talent but also at bolstering its operational capabilities as it navigates through a tumultuous period. Key Developments1. Equity Grants for New Employees: Codexis has approved equity grants for eight new hires, consisting of options to purchase 350,175 shares and 80,138 restricted stock units (RSUs). Notably, newly appointed Chief Financial Officer Georgia Erbez received a significant inducement, including an option to purchase 300,000 shares and 50,000 RSUs. This generous compensation package underscores the companyns commitment to attracting high-caliber professionals who can contribute to its strategic objectives.

Codexis Secures $40 Million Deal with Innovatus Capital Partners, Paving the Way for Breakthrough Biotechnology Innovations

During the 12-month period ending in the third quarter of 2023, Codexis Inc reported a cumulative net loss of $-82 million. Despite this setback, the company remains optimistic and committed to pushing forward with their innovative research and development projects.
The newly secured term loan agreement, which is expected to infuse the company with a substantial amount of capital, will allow Codexis Inc to accelerate their efforts and achieve significant milestones in the development of the ECO Synthesis manufacturing platform. This platform has the potential to revolutionize the production of RNAi therapeutics, opening doors to new treatment options and improving patient outcomes.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Basic Materials Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-05T12:14:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.